SCHEMBL2647434

SCHEMBL2647434

COC(=O)/C(=C/C1CCCC1)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.47
TAS1R2 Q8TE23 1/20 0.47
KMT2A Q03164 1/20 0.44
SLC6A3 Q01959 8/20 0.44
SSTR3 P32745 1/20 0.43
HPGD P15428 1/20 0.42
ATM Q13315 1/20 0.41
SIGMAR1 Q99720 1/20 0.40
TAS1R1 Q7RTX1 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
TSHR P16473 1/20 0.40
CYP2C19 P33261 1/20 0.40
CCR2 P41597 1/20 0.40
SLC6A2 P23975 1/20 0.39
SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2647437 1.00 TAS1R3 (0.47) TAS1R3TAS1R2KMT2ASLC6A3SSTR3
SCHEMBL2646441 0.83 TSHR (0.47) TAS1R3TAS1R2KMT2AHPGDSIGMAR1
SCHEMBL2646437 0.83 TSHR (0.47) TAS1R3TAS1R2KMT2AHPGDSIGMAR1
SCHEMBL2645735 0.82 GCK (0.42) TAS1R3TAS1R2KMT2ATAS1R1
SCHEMBL2651148 0.82 GCK (0.35) TAS1R3TAS1R2KMT2ASLC6A3SSTR3
SCHEMBL2645730 0.82 GCK (0.42) TAS1R3TAS1R2KMT2ATAS1R1
SCHEMBL2650347 0.81 GCK (0.34) TAS1R3TAS1R2KMT2ASLC6A3SSTR3
SCHEMBL2649681 0.81 GCK (0.34) TAS1R3TAS1R2KMT2ASLC6A3SSTR3
SCHEMBL2646968 0.80 TAS1R3 (0.46) TAS1R3TAS1R2KMT2ASLC6A3SSTR3
SCHEMBL2646970 0.80 TAS1R3 (0.46) TAS1R3TAS1R2KMT2ASLC6A3SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1242397-B1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2005-09-28 EP disclosed
EP-1242397-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2002-09-25 EP disclosed
US-6353111-B1 WHICH INCREASE INSULIN SECRETION IN THE TREATMENT OF TYPE II DIABETES; 2,3-DI-SUBSTITUTED TRANS OLEFINIC N-HETEROAROMATIC OR URIDO PROPIONAMIDES: THE SUBSTITUTION AT THE 2-POSITION BEING A SUBSTITUTED PHENYL GROUP AND AT THE 3-POSITION A HOFFMANN-LA ROCHE INC. 2002-03-05 US disclosed
WO-2001044216-A1 TRANS OLEFINIC GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2001-06-21 WO disclosed